VIVEbiotech and Zelluna Advance Off-the-Shelf TCR-NK Cell Therapy for Solid Tumors Toward 2026 Clinical Trials
核心洞察
VIVEbiotech (搜索) and Zelluna (搜索)'s collaboration since 2018 focuses on GMP lentiviral vector manufacturing for allogeneic TCR-NK cell therapies targeting solid tumors (搜索).
Zelluna (搜索)'s lead candidate ZI-MA4-1, targeting MAGE-A4, is planned to enter clinical trials in 2026 as an off-the-shelf therapy.
The partnership addresses key manufacturing challenges including scalability, high purity, consistent quality, and cost-efficiency for allogeneic cell therapies.
VIVEbiotech (搜索) and Zelluna (搜索) have disclosed details of a long-running collaboration focused on GMP lentiviral vector manufacturing for Zelluna's allogeneic T cell receptor-based natural killer (TCR-NK) cell therapy platform. The partnership, active since 2018, underpins Zelluna's efforts to develop off-the-shelf therapies for solid tumors (搜索), with its lead MAGE-A4-targeting candidate, ZI-MA4-1, planned to enter clinical trials in 2026.
The collaboration leverages complementary expertise: Zelluna (搜索) concentrates on advancing its TCR-NK cell therapy platform while VIVEbiotech (搜索) provides a reliable, scalable, and GMP-compliant lentiviral vector manufacturing platform. "Our established processes enable fast turnaround times, scalability without loss of quality, and high reproducibility, ensuring that Zelluna receives consistent vector supply to support development milestones," said Jon Alberdi, CEO of VIVEbiotech.
Manufacturing Challenges in Allogeneic Cell Therapies
Manufacturing lentiviral vectors for allogeneic cell therapies presents distinct challenges. According to Alberdi, achieving a combination of high purity, consistent quality, and scalability is paramount. "As these therapies rely on producing large batches upfront to support multiple patients, the manufacturing process must be robust and reproducible at increasing scales without compromising vector quality," he explained. Lentiviral vectors must also be thoroughly characterized to ensure safety and performance, placing high demands on process control, analytics, and GMP compliance.
Lentiviral vector performance directly impacts the feasibility of off-the-shelf therapies. Higher-performing vectors enable efficient gene transfer at lower doses, contributing to improved safety profiles and more predictable manufacturing outcomes. As allogeneic cell therapies expand toward broader patient populations and indications with higher incidence rates, well-characterized, high-performing vectors become increasingly critical for scalable manufacturing and regulatory approval.
Solid Tumors (搜索) Versus Blood Cancers: Divergent Manufacturing Demands
The shift toward solid tumor indications introduces additional manufacturing complexity. "From a manufacturing standpoint, the growing focus on solid tumors (搜索) brings an increased need for process reliability and consistency, as developers explore more complex therapeutic approaches and indications with significant unmet medical need," Alberdi noted. While solid tumors have historically been more challenging to treat, advances in gene and cell therapy technologies are creating new opportunities. Flexible, scalable platforms that support innovation while maintaining GMP standards are essential, and the use of stable cell lines is a key contributor to achieving this goal.
The Path to Broader Patient Access
Making off-the-shelf solid tumor therapies more widely accessible will require continued investment in scalable platforms, automation, and streamlined quality control. VIVEbiotech (搜索) is actively incorporating automation across manufacturing, quality control, and documentation workflows with the goal of supporting cost-effective production. "As more companies adopt allogeneic approaches and gain experience with these technologies, collective knowledge around manufacturing processes will continue to grow, leading to improved yields, greater efficiency, and reduced costs," Alberdi said.
The collaboration between VIVEbiotech (搜索) and Zelluna (搜索) exemplifies how strategic partnerships can accelerate progress toward clinical readiness, with the upcoming 2026 clinical trial entry for ZI-MA4-1 representing a significant milestone for the TCR-NK cell therapy field.